VOL. XCIV, NO. 247
★ WIDE MOAT STOCKS COMPARISON ★
NO ADVICE
Saturday, January 3, 2026
Stock Comparison
AstraZeneca PLC vs Pro Medicus Limited
Compare moat strength, market structure, and segment coverage to understand how each company defends its edge.
AstraZeneca PLC
AZN · London Stock Exchange
Weighted average of segment moat scores, combining moat strength, durability, confidence, market structure, pricing power, and market share.
Full stock profile
Dive deeper into AstraZeneca PLC's moat claims, evidence, and risks.
View AZN analysisPro Medicus Limited
PME · ASX
Weighted average of segment moat scores, combining moat strength, durability, confidence, market structure, pricing power, and market share.
Full stock profile
Dive deeper into Pro Medicus Limited's moat claims, evidence, and risks.
View PME analysisComparison highlights
- Moat score gap: Pro Medicus Limited leads (80 / 100 vs 71 / 100 for AstraZeneca PLC).
- Segment focus: AstraZeneca PLC has 6 segments (41% in Oncology); Pro Medicus Limited has 2 segments (92.5% in Visage 7 Enterprise Imaging Platform (PACS / CloudPACS)).
- Moat breadth: AstraZeneca PLC has 4 moat types across 3 domains; Pro Medicus Limited has 6 across 2.
Primary market context
AstraZeneca PLC
Oncology
Innovator oncology therapeutics (branded prescription medicines)
Global
Hospitals, oncology clinics, payers
Innovator biopharmaceutical company
41%
Pro Medicus Limited
Visage 7 Enterprise Imaging Platform (PACS / CloudPACS)
Enterprise imaging / PACS and related modules for hospitals and integrated delivery networks (IDNs)
Primarily North America; also Europe and Australia
Hospitals, imaging centers, integrated delivery networks (IDNs)
Healthcare IT software vendor / platform provider
92.5%
Side-by-side metrics
Moat coverage
Shared moat types
No overlap yet.
AstraZeneca PLC strengths
Pro Medicus Limited strengths
Segment mix
AstraZeneca PLC segments
Full profile >Oncology
Oligopoly
Cardiovascular, Renal and Metabolism (CVRM)
Competitive
Respiratory & Immunology (R&I)
Oligopoly
Vaccines & Immune Therapies (V&I)
Oligopoly
Rare Disease
Oligopoly
Other Medicines
Competitive
Pro Medicus Limited segments
Full profile >Visage 7 Enterprise Imaging Platform (PACS / CloudPACS)
Oligopoly
Visage RIS (Radiology Information System) and Promedicus.net
Oligopoly
Want the full wide moat stocks list?
Browse the full ranking of wide moat stocks, updated with moat scores and segment context.
View the moat stocks listCuration & Accuracy
This directory blends AI‑assisted discovery with human curation. Entries are reviewed, edited, and organized with the goal of expanding coverage and sharpening quality over time. Your feedback helps steer improvements (because no single human can capture everything all at once).
Details change. Pricing, features, and availability may be incomplete or out of date. Treat listings as a starting point and verify on the provider’s site before making decisions. If you spot an error or a gap, send a quick note and I’ll adjust.